Nuclear Medicine in Oncology

AbstractNuclear Medicine as medical science and clinical practice is known for its use of radiopharmaceuticals to diagnose, treat diseases and evaluate response to treatments. It spans the wide scope of all medical specialties since it is a functional, metabolic and molecular-based investigation of disease processes. The radiopharmaceutical as the basis for data acquisition, processing and analysis of information, is composed of two molecules – one the pharmaceutical is the pharmacologically active component with specific pharmacodynamics and pharmacokinetics, usually an analogue of another biologic molecule, the other a radionuclide (the source of detecting signal) with specific physicochemical properties. There are two main types of radionuclides, the single photon emitters and the positron emitters. The former enable data acquisition with gamma cameras and the latter are the signal source for Positron Emission Tomography (PET). Radiopharmaceuticals labelled with both types of radionuclides permit diagn...

[1]  L. Mortelmans,et al.  131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  D. Denoyer,et al.  Radionuclide Theranostics in Cancer , 2014 .

[3]  M. Bergström,et al.  In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. , 2010, Nuclear medicine and biology.

[4]  K. Ng,et al.  Therapeutic radionuclides in nuclear medicine: current and future prospects , 2014, Journal of Zhejiang University SCIENCE B.

[5]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[6]  Scott D Flamm,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  S. Stoeckli,et al.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Jose Morey,et al.  The bone scan. , 2012, Seminars in nuclear medicine.

[9]  Stephen T. C. Wong,et al.  Cancer Theranostics: An Introduction , 2014 .

[10]  W. Cai,et al.  Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment , 2007 .

[11]  Martin Gotthardt,et al.  Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small-Animal PET Scanner , 2010, Journal of Nuclear Medicine.

[12]  F. Roesch,et al.  Scandium-44: benefits of a long-lived PET radionuclide available from the (44)Ti/(44)Sc generator system. , 2012, Current radiopharmaceuticals.

[13]  V. Goh,et al.  PET/MRI in Oncological Imaging: State of the Art , 2015, Diagnostics.

[14]  P. Mikuš,et al.  Copper compounds in nuclear medicine and oncology , 2014 .

[15]  P. Mikuš,et al.  Gallium compounds in nuclear medicine and oncology , 2014 .

[16]  G. Germano,et al.  EANM/ESC guidelines for radionuclide imaging of cardiac function , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  R. Katz,et al.  Current concepts of anthracycline cardiotoxicity : pathogenesis, diagnosis and prevention , 2009 .

[18]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  W. Oyen,et al.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  D. Hörsch,et al.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  S. Srivastava.  The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m , 2007 .

[22]  F. Forrer,et al.  Peptide receptor radionuclide therapy , 2007 .

[23]  S. Bellis,et al.  Advantages of RGD peptides for directing cell association with biomaterials. , 2011, Biomaterials.

[24]  André Luxen,et al.  Aptamers as radiopharmaceuticals for nuclear imaging and therapy. , 2016, Nuclear medicine and biology.

[25]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[26]  A. Alavi,et al.  Current status of sentinel lymph-node biopsy in patients with breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  A. Kling,et al.  Radionuclides used for therapy and suggestion for new candidates , 2005 .

[28]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[29]  A. Chiti,et al.  EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  S. Filetti,et al.  Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. , 1999, European journal of endocrinology.

[31]  M. Mihm,et al.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  W. N. Tauxe,et al.  Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  J. Vercher-Conejero,et al.  PET/MRI: Applications in Clinical Imaging , 2013, Current Radiology Reports.

[34]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  I. Fogelman,et al.  Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. , 2009, Seminars in nuclear medicine.

[36]  H. Kühl.  Left ventricular function , 2011 .

[37]  DashAshutosh,et al.  Peptide Receptor Radionuclide Therapy: An Overview , 2015 .